Organovo Holdings appoints two directors
Mr. Kessel will become a member of the Nominating and Corporate Governance Committee and the Science and Technology Committee, while Mr. Maroun will join the Audit and Compensation Committees.
Mr. Kessel is a partner of Symphony Capital, a private equity firm he co-founded in 2002 that invests in biopharmaceutical company clinical development programs. He is also Of Counsel at Shearman & Sterling and a member of the firm’s capital markets group.
Previously, from 1971 to 2001, Mr. Kessel held various roles at Shearman & Sterling, including as managing partner leading the international law firm’s day-to-day operations. He has previously served on several public biopharmaceutical company boards.
Mr. Maroun is an executive partner at Frazier Healthcare Partners, a private equity and venture capital firm specializing in healthcare-focused investments.
Before joining Frazier in 2015, he was senior vice president and general counsel of Aptalis Pharmaceuticals from 2012 to 2014.
Mr. Maroun has also held numerous senior executive roles for APP Pharmaceuticals, Abraxis BioScience and American BioScience Inc.
He has worked with major financial organizations and independent law firms, and has held both legal and financial positions with companies including Merrill Lynch, Deloitte & Touche and McDonough, Holland & Allen.
Mr. Maroun currently serves on the board of Leiter’s Enterprises, a private portfolio company of Frazier Healthcare Partners, and the Board of Trustees of John Carroll University. ■
LATEST MOVES FROM California
- Impax Laboratories appoints Paul M. Bisaro as CEO
- Retrophin names John A. Orwin to board
- Intel appoints two to board
- Walt Disney Company extends CEO's contract to 2019
- Ekso Bionics adds Howard Palefsky to board
More inside POST